To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Exhibit 99.1 There can be no assurance that the process will result in any such transaction. VYNE's Board of Directors has not set a timetable for the strategic review process. VYNE does not intend to provide updates until the Board approves a specific action or otherwise determines that disclosure is appropriate or required. The Company has engaged LifeSci Capital as a financial advisor to assist in the strategic review process. Pipeline Overview VYN202, an oral small molecule BD2-selective BET inhibitor: ...

Company is progressing its previously initiated strategic review evaluating a range of options to maximize shareholder value, including assessment of internal pipeline opportunities and broader strategic alternatives12-week, non-clinical toxicology study of VYN202 in dogs to remedy the partial hold in male clinical subjects is ongoing; Company continues to evaluate potential opportunities for VYN202 as a treatment for serious, immune-mediated diseases Cash runway into first half of 2027 based on previously ...

[PART I – FINANCIAL INFORMATION](index=5&type=section&id=Part%20I%20%E2%80%93%20FINANCIAL%20INFORMATION) [Item 1. Unaudited Financial Statements](index=5&type=section&id=Item%201.%20Unaudited%20Financial%20Statements) This section presents VYNE Therapeutics Inc.'s unaudited condensed consolidated financial statements, including balance sheets, statements of operations, changes in equity, cash flows, and notes, detailing financial position and performance for periods ended June 30, 2025, and December 31, 2024 [Unaudited Condensed Consolidated Balance Sheets](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) The balance sheets show the company's financial position, with total assets decreasing from $66.9 million to $44.7 million, primarily due to a reduction in marketable securities | Metric | June 30, 2025 (in thousands) | December 31, 2024 (in thousands) | | :----------------------------- | :----------------------------- | :----------------------------- | | Cash and cash equivalents | $22,047 | $19,926 | | Investment in marketable securities | $17,600 | $41,590 | | Total Current Assets | $44,343 | $64,437 | | Total Assets | $44,718 | $66,905 | | Total Current Liabilities | $5,836 | $14,819 | | Total Liabilities | $5,836 | $14,819 | | Total Stockholders' Equity | $38,882 | $52,086 | [Unaudited Condensed Consolidated Statements Of Operations and Comprehensive Loss](index=7&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20Of%20Operations%20and%20Comprehensive%20Loss) The statements of operations show a reduced net loss for both the three and six months ended June 30, 2025, compared to the prior year, driven by lower operating expenses and increased other income | Metric (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Royalty revenues | $69 | $198 | $271 | $296 | | Research and development | $4,881 | $7,306 | $11,004 | $11,014 | | General and administrative | $2,730 | $3,288 | $6,005 | $7,058 | | Operating loss | $(7,542) | $(10,396) | $(16,738) | $(17,776) | | Other income, net | $1,795 | $1,001 | $2,388 | $2,140 | | Net loss | $(5,755) | $(9,406) | $(14,366) | $(15,655) | | Loss per share, basic and diluted | $(0.13) | $(0.22) | $(0.34) | $(0.37) | [Unaudited Condensed Consolidated Statements Of Changes In Stockholders' Equity](index=8&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20Of%20Changes%20In%20Stockholders'%20Equity) Stockholders' equity decreased from $52.1 million at January 1, 2025, to $38.9 million at June 30, 2025, primarily due to the net loss incurred during the period, partially offset by stock-based compensation | Metric (in thousands) | January 1, 2025 | June 30, 2025 | | :-------------------- | :-------------- | :------------ | | Total Stockholders' Equity | $52,086 | $38,882 | | Net loss | — | $(14,366) | | Stock-based compensation | — | $1,292 | | Cashless exercise of pre-funded warrants (shares) | — | 4,813,611 | [Unaudited Condensed Consolidated Statements Of Cash Flows](index=10&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20Of%20Cash%20Flows) Net cash used in operating activities increased to $22.3 million in H1 2025, while investing activities provided $24.5 million, mainly from marketable securities sales, increasing cash | Cash Flow Activity (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------------- | :----------------------------- | :----------------------------- | | Net cash used in operating activities | $(22,264) | $(16,463) | | Net cash provided by investing activities | $24,506 | $15,451 | | Net cash used in financing activities | $(121) | $(7) | | Cash, cash equivalents and restricted cash at end of period | $22,047 | $29,655 | [Notes to Unaudited Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) These notes detail the company's operations, accounting policies, strategic agreements, and financial components, providing comprehensive context for the condensed consolidated financial statements [NOTE 1 - NATURE OF OPERATIONS](index=11&type=section&id=NOTE%201%20-%20NATURE%20OF%20OPERATIONS) VYNE Therapeutics, a clinical-stage biopharmaceutical company, focuses on BET inhibitors, with VYN202 facing a clinical hold and repibresib gel being discontinued - VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need[34](index=34&type=chunk) - VYN202, an oral, small molecule BD2-selective BET inhibitor, initiated a Phase 1b trial in February 2025 for moderate-to-severe plaque psoriasis, but the FDA verbally placed a clinical hold in April 2025 due to testicular toxicity in dogs[36](index=36&type=chunk)[37](index=37&type=chunk) - Following the clinical hold, the company unblinded preliminary Phase 1b data from seven subjects, showing improvement in signs and symptoms for VYN202-treated subjects, leading to the termination of the psoriasis trial to advance VYN202 into other serious, immune-mediated diseases[38](index=38&type=chunk)[39](index=39&type=chunk) - Repibresib gel (VYN201) Phase 2b trial in nonsegmental vitiligo did not meet its primary or key secondary endpoints, resulting in the discontinuation of the trial and the company seeking an external partner for its continued development[40](index=40&type=chunk)[41](index=41&type=chunk) - As of June 30, 2025, the Company had cash, cash equivalents and marketable securities of **$39.6 million** and an accumulated deficit of **$745.5 million**[43](index=43&type=chunk) [NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES](index=12&type=section&id=NOTE%202%20-%20SIGNIFICANT%20ACCOUNTING%20POLICIES) This note details accounting principles, including U.S. GAAP, revenue recognition, R&D expensing, fair value, income tax policies, ERTC, and new pronouncements - The unaudited condensed consolidated financial statements are prepared in accordance with U.S. GAAP for interim financial statements[47](index=47&type=chunk) - Royalty revenues from Finacea foam are recognized when the product is sold by LEO Pharma[59](index=59&type=chunk) - All research and development expenses are expensed as incurred[68](index=68&type=chunk) - The Company recognized **$1.3 million** of other income for both the three and six months ended June 30, 2025, due to the closure of the IRS examination of its ERTC filings[81](index=81&type=chunk) - The Company's net operating loss (NOL) carryforwards are subject to annual limitations under Section 382 of the Internal Revenue Code, with ownership changes through March 31, 2025, expected to result in unutilized federal NOLs[76](index=76&type=chunk) - The Company is evaluating the impact of newly issued accounting pronouncements, ASU No. 2023-09 (Income Tax Disclosures) and ASU No. 2024-03 (Disaggregation of Income Statement Expenses)[83](index=83&type=chunk)[84](index=84&type=chunk) [NOTE 3 - STRATEGIC AGREEMENTS](index=17&type=section&id=NOTE%203%20-%20STRATEGIC%20AGREEMENTS) This note details licensing agreements with Tay Therapeutics for BET inhibitor programs, outlining financial obligations, and the sale of the MST Franchise - The Company holds exclusive worldwide rights to research, develop, and commercialize Tay's small molecule BET inhibitor compounds[85](index=85&type=chunk) Tay Therapeutics License Agreements Financial Obligations | Agreement | Upfront Payment | Milestone Payments (U.S.) | Paid/Accrued Milestones (through June 30, 2025) | Tiered Royalties on Net Sales | | :-------------------------- | :-------------- | :-------------------------- | :---------------------------------------------- | :---------------------------- | | Repibresib License Agreement | $0.5 million | Up to $15.75 million | $1.8 million | 5%, 7.5%, 10% | | VYN202 License Agreement | $3.75 million | Up to $43.75 million | $1.3 million | 5%, 7.5%, 10% | - The Company sold its MST Franchise to Journey Medical Corporation in January 2022, receiving **$20.0 million** upfront and **$5.0 million** deferred payment, and is eligible for up to **$450.0 million** in aggregate sales milestone payments[93](index=93&type=chunk) [NOTE 4 – DISCONTINUED OPERATIONS](index=19&type=section&id=NOTE%204%20%E2%80%93%20DISCONTINUED%20OPERATIONS) The MST Franchise, sold in January 2022, is classified as discontinued operations, with minimal losses for the reported periods, consisting solely of general and administrative expenses Loss from Discontinued Operations, Net of Income Taxes (in thousands) | Period | 2025 | 2024 | | :-------------------------- | :--- | :--- | | Three Months Ended June 30, | $8 | $11 | | Six Months Ended June 30, | $16 | $19 | - Milestone payments for sales of ZILXI, AMZEEQ, and FCD105 are accounted for as a gain contingency and will be recognized in earnings when realizable[96](index=96&type=chunk) [NOTE 5 – FAIR VALUE MEASUREMENTS](index=19&type=section&id=NOTE%205%20%E2%80%93%20FAIR%20VALUE%20MEASUREMENTS) The company's financial assets measured at fair value are categorized into Level 1 and Level 2, with cash and cash equivalents split and marketable securities entirely in Level 2 as of June 30, 2025 Fair Value of Financial Assets (in thousands) | Asset Category | June 30, 2025 (Level 1) | June 30, 2025 (Level 2) | December 31, 2024 (Level 1) | December 31, 2024 (Level 2) | | :------------- | :---------------------- | :---------------------- | :-------------------------- | :-------------------------- | | Cash and cash equivalents | $21,450 | $597 | $19,926 | $0 | | Marketable securities | $0 | $17,600 | $0 | $41,590 | | Total assets | $21,450 | $18,197 | $19,926 | $41,590 | [NOTE 6 – MARKETABLE SECURITIES](index=20&type=section&id=NOTE%206%20%E2%80%93%20MARKETABLE%20SECURITIES) Marketable securities, primarily U.S. Treasury bills, significantly decreased from $41.6 million to $17.6 million, shifting from an unrealized gain to an unrealized loss Marketable Securities (in thousands) | Security Type | June 30, 2025 | December 31, 2024 | | :------------ | :------------ | :---------------- | | U.S. Government and agency debt securities | $0 | $10,572 | | U.S. Treasury bills | $17,600 | $31,018 | | Total | $17,600 | $41,590 | - As of June 30, 2025, marketable securities were in an unrealized loss position of **$(2) thousand**, compared to an unrealized gain position of **$20 thousand** as of December 31, 2024[100](index=100&type=chunk) [NOTE 7 - PROPERTY AND EQUIPMENT](index=20&type=section&id=NOTE%207%20-%20PROPERTY%20AND%20EQUIPMENT) The company's property and equipment, mainly office equipment, showed a slight decrease in net value from $113 thousand at December 31, 2024, to $102 thousand at June 30, 2025, due to depreciation Property and Equipment, Net (in thousands) | Metric | June 30, 2025 | December 31, 2024 | | :------------------------ | :------------ | :---------------- | | Office equipment | $117 | $117 | | Less: Accumulated depreciation | $(15) | $(4) | | Property and equipment, net | $102 | $113 | - Depreciation expense for the six months ended June 30, 2025, totaled **$12 thousand**[102](index=102&type=chunk) [NOTE 8 – STOCKHOLDERS' EQUITY](index=21&type=section&id=NOTE%208%20%E2%80%93%20STOCKHOLDERS'%20EQUITY) This note details authorized and outstanding shares, at-the-market offerings, and the exercise and remaining balance of Pre-Funded Warrants - As of June 30, 2025, **19,773,784 shares** of common stock were issued and outstanding[21](index=21&type=chunk) - No shares of common stock were sold under the Cowen Sales Agreement (at-the-market offering program) during the six months ended June 30, 2025 and 2024[107](index=107&type=chunk) - During the six months ended June 30, 2025, **4,813,940 Pre-Funded Warrants** were exercised via a net exercise mechanism, with **23,028,800 Pre-Funded Warrants** remaining outstanding[109](index=109&type=chunk) - The company also had **27,509 other warrants** outstanding as of June 30, 2025, with an exercise price of **$8.40** and an expiration date of July 29, 2026[110](index=110&type=chunk) [NOTE 9 – STOCK-BASED COMPENSATION](index=22&type=section&id=NOTE%209%20%E2%80%93%20STOCK-BASED%20COMPENSATION) This note outlines equity incentive plans and details stock-based compensation expenses, which decreased for both the three and six months ended June 30, 2025 - During the six months ended June 30, 2025, the Company granted **1,582,500 options** to employees and directors with exercise prices ranging from **$1.80 to $2.77**, and a fair value of **$3.6 million**[117](index=117&type=chunk) Stock-Based Compensation Expenses (in thousands) | Expense Category | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and development | $61 | $133 | $187 | $296 | | General and administrative | $468 | $752 | $1,105 | $1,574 | | Total | $529 | $885 | $1,292 | $1,870 | [NOTE 10 – COMMITMENTS AND CONTINGENCIES](index=23&type=section&id=NOTE%2010%20%E2%80%93%20COMMITMENTS%20AND%20CONTINGENCIES) The company is not currently involved in any legal proceedings or claims that management believes are likely to have a material adverse effect on its business - As of June 30, 2025, there were no claims or actions pending against the Company that are likely to have a material adverse effect[120](index=120&type=chunk) [NOTE 11 - SEGMENT INFORMATION](index=23&type=section&id=NOTE%2011%20-%20SEGMENT%20INFORMATION) The company operates as a single segment, focusing on developing therapies for chronic inflammatory and immune-mediated conditions, with the CEO reviewing key expenses - The Company operates in one operating segment, focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions[121](index=121&type=chunk)[124](index=124&type=chunk) - The Chief Executive Officer (CEO) acts as the Chief Operating Decision Maker (CODM), evaluating net loss, specific R&D program spend, and overall general and administrative expenses[122](index=122&type=chunk) Research and Development Expenses by Product Candidate (in thousands) | Product Candidate | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :---------------- | :----------------------------- | :----------------------------- | | Repibresib (VYN201) | $5,041 | $6,426 | | VYN202 | $4,184 | $2,901 | [NOTE 12 - SUBSEQUENT EVENTS](index=24&type=section&id=NOTE%2012%20-%20SUBSEQUENT%20EVENTS) On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was signed into law, making comprehensive revisions to federal corporate income tax provisions, which the company is currently evaluating - The One Big Beautiful Bill Act (OBBBA), signed on July 4, 2025, revises federal corporate income tax provisions, including R&D expense treatment and full expensing of business assets[125](index=125&type=chunk) - The Company is evaluating the potential impact of OBBBA on its condensed consolidated financial statements, as it was enacted after the June 30, 2025 balance sheet date[126](index=126&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on financial condition and operations, focusing on BET inhibitor development, product candidates, liquidity, and performance [Company Overview](index=25&type=section&id=Company%20Overview) VYNE Therapeutics, a clinical-stage biopharmaceutical company, focuses on BET inhibitors, with VYN202's trial terminated and repibresib gel discontinued - VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, utilizing its InhiBET™ portfolio of small molecule BET inhibitors[128](index=128&type=chunk)[129](index=129&type=chunk) - VYN202, an oral BD2-selective BET inhibitor, had its Phase 1b trial in plaque psoriasis placed on clinical hold by the FDA due to testicular toxicity in dogs; however, promising preliminary unblinded data led to the trial's termination to advance VYN202 into other serious, immune-mediated diseases[131](index=131&type=chunk)[132](index=132&type=chunk)[133](index=133&type=chunk) - Repibresib gel (VYN201) Phase 2b trial in nonsegmental vitiligo did not meet its primary or key secondary endpoints, leading to the discontinuation of the trial and the company seeking an external partner for its continued development[135](index=135&type=chunk) - The company has implemented cost reductions expected to extend its cash runway into the **first half of 2027**[134](index=134&type=chunk) [Development and License Agreements](index=26&type=section&id=Development%20and%20License%20Agreements) This section details licensing agreements with Tay Therapeutics for Repibresib and VYN202, outlining financial obligations, and the MST Franchise sale terms - The Company holds exclusive worldwide rights to Tay's BET inhibitor compounds for the treatment of any disease, disorder, or condition in humans[139](index=139&type=chunk) Tay Therapeutics License Agreements Financial Obligations | Agreement | Upfront Payment | Milestone Payments (U.S.) | Paid/Accrued Milestones (through June 30, 2025) | Tiered Royalties on Net Sales | | :-------------------------- | :-------------- | :-------------------------- | :---------------------------------------------- | :---------------------------- | | Repibresib License Agreement | $0.5 million | Up to $15.75 million | $1.8 million | 5%, 7.5%, 10% | | VYN202 License Agreement | $3.75 million | Up to $43.75 million | $1.3 million | 5%, 7.5%, 10% | - The Company sold its MST Franchise to Journey Medical Corporation in January 2022, receiving **$20.0 million** upfront and **$5.0 million** deferred payment, and is eligible for up to **$450.0 million** in aggregate sales milestone payments[93](index=93&type=chunk) [Components of Operating Results](index=28&type=section&id=Components%20of%20Operating%20Results) This section explains key drivers of financial performance, including royalty revenues, R&D, G&A, other income, and the impact of NOLs and Section 382 limitations - Royalty revenues from Finacea foam were **$0.1 million** for the three months ended June 30, 2025, and **$0.3 million** for the six months ended June 30, 2025[147](index=147&type=chunk) - Research and development expenses decreased by **33.2%** for the three months ended June 30, 2025, compared to the prior year, primarily due to decreased expenses for repibresib and VYN202[148](index=148&type=chunk)[156](index=156&type=chunk) - General and administrative expenses decreased by **17.0%** for the three months ended June 30, 2025, compared to the prior year[149](index=149&type=chunk)[157](index=157&type=chunk) - Other income, net, increased by **79.3%** for the three months ended June 30, 2025, primarily due to the recognition of **$1.3 million** related to the closure of the IRS examination period of the Company's ERTC filings[158](index=158&type=chunk) - As of December 31, 2024, the Company had federal NOL carryforwards of **$343.4 million** and state NOLs of **$53.6 million**, with **$40.2 million** of federal NOLs expected to expire unutilized due to Section 382 ownership changes[152](index=152&type=chunk)[153](index=153&type=chunk) [Results of Operations](index=29&type=section&id=Results%20of%20Operations) This section provides a detailed comparison of the company's financial performance for the three and six months ended June 30, 2025, versus 2024, highlighting changes in revenues, operating expenses, other income, and net loss [Comparison of the Three Months Ended June 30, 2025 and 2024](index=29&type=section&id=Comparison%20of%20the%20Three%20Months%20Ended%20June%2030%2C%202025%20and%202024) For Q2 2025, net loss decreased by 38.8% to $5.8 million, driven by reduced R&D and G&A expenses and increased other income Financial Performance (Three Months Ended June 30, in thousands) | Metric | 2025 | 2024 | Change ($) | Change (%) | | :-------------------------- | :--- | :--- | :--------- | :--------- | | Royalty revenues | $69 | $198 | $(129) | (65.2)% | | Research and development | $4,881 | $7,306 | $(2,425) | (33.2)% | | General and administrative | $2,730 | $3,288 | $(558) | (17.0)% | | Other income, net | $1,795 | $1,001 | $794 | 79.3% | | Net loss | $(5,755) | $(9,406) | $(3,651) | (38.8)% | - The decrease in R&D expenses was primarily due to the timing of expenses for the repibresib Phase 2b trial and VYN202 Phase 1 trials, including milestone payments in the prior year[156](index=156&type=chunk) [Comparison of the Six Months Ended June 30, 2025 and 2024](index=31&type=section&id=Comparison%20of%20the%20Six%20Months%20Ended%20June%2030%2C%202025%20and%202024) For H1 2025, net loss decreased by 8.2% to $14.4 million, mainly due to decreased G&A expenses and increased other income Financial Performance (Six Months Ended June 30, in thousands) | Metric | 2025 | 2024 | Change ($) | Change (%) | | :-------------------------- | :--- | :--- | :--------- | :--------- | | Royalty revenues | $271 | $296 | $(25) | (8.4)% | | Research and development | $11,004 | $11,014 | $(10) | (0.1)% | | General and administrative | $6,005 | $7,058 | $(1,053) | (14.9)% | | Other income, net | $2,388 | $2,140 | $248 | 11.6% | | Net loss | $(14,366) | $(15,655) | $(1,289) | (8.2)% | - The slight decrease in R&D expenses was driven by a **$1.4 million** decrease for repibresib, partially offset by a **$1.3 million** increase for VYN202 due to Phase 1b trial costs[163](index=163&type=chunk) [Liquidity and Capital Resources](index=32&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company had $39.6 million in cash and marketable securities, sufficient for 12 months, but needs substantial additional capital - As of June 30, 2025, the Company had cash, cash equivalents and marketable securities of **$39.6 million** and an accumulated deficit of **$745.5 million**[168](index=168&type=chunk) - For the six months ended June 30, 2025, the Company incurred a net loss of **$14.4 million** and used **$22.3 million** of cash in operations[168](index=168&type=chunk) - The Company believes its existing cash, cash equivalents and marketable securities are sufficient to fund its operating and capital expenditure requirements for a period of at least **12 months**[168](index=168&type=chunk) - The Company will require substantial additional capital to complete the development of VYN202 and any future product candidates[171](index=171&type=chunk) - The amount of proceeds the Company can raise through primary public offerings using its Form S-3 is limited to **one-third** of the aggregate market value of shares held by non-affiliates until its public float exceeds **$75.0 million**[172](index=172&type=chunk) Cash Flows (Six Months Ended June 30, in thousands) | Cash Flow Activity | 2025 | 2024 | | :----------------- | :--- | :--- | | Operating activities | $(22,264) | $(16,463) | | Investing activities | $24,506 | $15,451 | | Financing activities | $(121) | $(7) | [Critical Accounting Policies, Significant Judgments and Use of Estimates](index=34&type=section&id=Critical%20Accounting%20Policies%2C%20Significant%20Judgments%20and%20Use%20of%20Estimates) The company's critical accounting policies, significant judgments, and use of estimates remain consistent with those disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 - There have been no material changes to the Company's critical accounting policies for the six months ended June 30, 2025[183](index=183&type=chunk) [Off-Balance Sheet Arrangements](index=34&type=section&id=Off-Balance%20Sheet%20Arrangements) The company is not party to any off-balance sheet arrangements that are expected to have a material current or future effect on its financial condition, revenues, expenses, results of operations, liquidity, capital expenditures, or capital resources - The Company is not party to any off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on its financial condition[184](index=184&type=chunk) [Recently Issued and Adopted Accounting Pronouncements](index=35&type=section&id=Recently%20Issued%20and%20Adopted%20Accounting%20Pronouncements) This section refers to Note 2 for a discussion of recently adopted and not yet adopted accounting pronouncements and their expected financial impact - Refer to 'Note 2 - Significant Accounting Policies' for a discussion of recently adopted accounting pronouncements and those not yet adopted[185](index=185&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=35&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, VYNE Therapeutics Inc. is not required to provide the detailed quantitative and qualitative disclosures about market risk typically found in this item - The Company is a smaller reporting company and is not required to provide quantitative and qualitative disclosures about market risk[186](index=186&type=chunk) [Item 4. Controls and Procedures](index=35&type=section&id=Item%204.%20Controls%20and%20Procedures) This section details the company's evaluation of its disclosure controls and procedures and reports on any changes in internal control over financial reporting [Evaluation of Disclosure Controls and Procedures](index=35&type=section&id=Evaluation%20of%20Disclosure%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2025 - Management concluded that the Company's disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2025[188](index=188&type=chunk) [Changes in Internal Control over Financial Reporting](index=35&type=section&id=Changes%20in%20Internal%20Control%20over%20Financial%20Reporting) There were no material changes in the company's internal control over financial reporting during the three months ended June 30, 2025 - There were no material changes in internal control over financial reporting during the three months ended June 30, 2025[189](index=189&type=chunk) [PART II – OTHER INFORMATION](index=35&type=section&id=Part%20II%20%E2%80%93%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=35&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any litigation or legal proceedings that management believes are likely to have a material adverse effect on its business - There are currently no claims or actions pending against the Company that are likely to have a material adverse effect on its business[190](index=190&type=chunk) [Item 1A. Risk Factors](index=35&type=section&id=Item%201A.%20Risk%20Factors) This section updates risk factors, emphasizing high drug development costs, clinical trial failures, funding needs, trade policy impacts, and Nasdaq delisting risk - Drug development is very expensive, time-consuming, and uncertain, with most product candidates failing to achieve regulatory approval[192](index=192&type=chunk)[193](index=193&type=chunk) - The FDA placed a clinical hold on the VYN202 Phase 1b trial due to testicular toxicity in dogs, requiring additional non-clinical studies to resume trials in male subjects[200](index=200&type=chunk) - The Phase 2b trial of repibresib gel in nonsegmental vitiligo failed to meet its primary and key secondary endpoints, leading to the termination of the trial[194](index=194&type=chunk) - The Company will need substantial additional funding to pursue its business objectives, and failure to raise capital could force it to curtail planned operations[208](index=208&type=chunk)[209](index=209&type=chunk) - International trade policies, including tariffs and trade barriers, may adversely affect the business, potentially increasing R&D expenses and supply chain complexity, especially given API manufacturing in China[203](index=203&type=chunk)[204](index=204&type=chunk)[205](index=205&type=chunk) - Failure to maintain compliance with Nasdaq continued listing requirements, such as the minimum bid price, could result in the delisting of the common stock, negatively affecting market price and liquidity[213](index=213&type=chunk)[216](index=216&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=39&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During Q2 2025, the company issued 3.7 million common shares upon net exercise of Pre-Funded Warrants, exempt from registration under Section 3(a)(9) - During the three months ended June 30, 2025, the Company issued **3,765,320 shares** of common stock upon the net exercise of Pre-Funded Warrants[217](index=217&type=chunk) - The issuances were exempt from registration under Section 3(a)(9) of the Securities Act of 1933, as an exchange with an existing security holder where no commission or other remuneration is paid[217](index=217&type=chunk) [Item 3. Defaults Upon Senior Securities](index=40&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities during the period - No defaults upon senior securities were reported[218](index=218&type=chunk) [Item 4. Mine Safety Disclosures](index=40&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's operations - This item is not applicable[219](index=219&type=chunk) [Item 5. Other Information](index=40&type=section&id=Item%205.%20Other%20Information) During the three months ended June 30, 2025, none of the company's directors or officers adopted or terminated any Rule 10b5-1 plans or other trading arrangements for the purchase or sale of its securities - None of the Company's directors and officers adopted or terminated any Rule 10b5-1 plans or other trading arrangements during the three months ended June 30, 2025[220](index=220&type=chunk) [Item 6. Exhibits](index=41&type=section&id=Item%206.%20Exhibits) This section lists all documents filed or furnished as exhibits to the Quarterly Report on Form 10-Q, including certifications from the Chief Executive Officer and Chief Financial Officer, and XBRL documents - The exhibits include certifications from the Chief Executive Officer and Chief Financial Officer (pursuant to Sections 302 and 906 of Sarbanes-Oxley Act of 2002) and XBRL documents[221](index=221&type=chunk) - Certifications attached as Exhibit 32.1 and Exhibit 32.2 are not deemed filed with the SEC[221](index=221&type=chunk) [SIGNATURES](index=42&type=section&id=SIGNATURES) The report is duly signed on behalf of VYNE Therapeutics Inc. by its Chief Executive Officer, David Domzalski, and Chief Financial Officer, Tyler Zeronda - The report is signed by David Domzalski, Chief Executive Officer, and Tyler Zeronda, Chief Financial Officer[225](index=225&type=chunk)

Group 1 - VYNE Therapeutics Inc. reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.23, representing an earnings surprise of +43.48% [1] - The company posted revenues of $0.07 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 31%, and a decline from $0.2 million in the same quarter last year [2] - VYNE Therapeutics shares have decreased by approximately 89.6% since the beginning of the year, contrasting with the S&P 500's gain of 10% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $0.15 million, and for the current fiscal year, it is -$0.94 on revenues of $0.6 million [7] - The Medical - Drugs industry, to which VYNE Therapeutics belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

[Phase 2b Trial Results for Repibresib Gel in Nonsegmental Vitiligo and Company Strategy](index=1&type=section&id=Phase%202b%20Trial%20Results%20for%20Repibresib%20Gel%20in%20Nonsegmental%20Vitiligo%20and%20Company%20Strategy) This section details the Phase 2b trial outcomes for Repibresib gel in nonsegmental vitiligo, including efficacy, safety, and the company's strategic decision to seek a partner for its continued development [Executive Summary of Trial Results and Company Actions](index=1&type=section&id=Executive%20Summary%20of%20Trial%20Results%20and%20Company%20Actions) The Phase 2b trial for Repibresib gel in nonsegmental vitiligo did not meet its primary (F-VASI50) or key secondary (F-VASI75) endpoints, leading VYNE to terminate the extension phase and seek an external partner - Trial did not meet primary endpoint (F-VASI50) or key secondary endpoint (F-VASI75)[1](index=1&type=chunk)[2](index=2&type=chunk)[4](index=4&type=chunk) - Repibresib 3% showed nominally statistically significant effects in percent change from baseline in **F-VASI (-43.6% vs. Vehicle: -25.6%)** and **T-VASI (-28.3% vs. Vehicle: -16.2%)**[2](index=2&type=chunk)[4](index=4&type=chunk) - Company believes results were impacted by unusually high vehicle effect and higher-than-expected dropout rate in active arms (**Repibresib 3%: 36.6%; Vehicle: 10.6%**)[2](index=2&type=chunk)[4](index=4&type=chunk) - VYNE will terminate the extension phase of the trial and seek an external partner for Repibresib[2](index=2&type=chunk)[4](index=4&type=chunk) - The company remains confident in its InhiBET BET inhibitor platform[4](index=4&type=chunk) [Phase 2b Trial Design and Methodology](index=1&type=section&id=Phase%202b%20Trial%20Design%20and%20Methodology) The Phase 2b trial was a randomized, double-blind, vehicle-controlled, multi-center study evaluating Repibresib gel at 1%, 2%, and 3% concentrations in 177 subjects with nonsegmental vitiligo - Trial design: Randomized, double-blind, vehicle-controlled, multi-center[3](index=3&type=chunk) - Subjects: **177 subjects** (mITT population) with nonsegmental vitiligo[3](index=3&type=chunk) - Dosing: Repibresib gel at **1%, 2%, and 3% concentrations**, once daily (QD)[3](index=3&type=chunk) - Primary endpoint: Proportion of subjects achieving F-VASI50 at Week 24 versus vehicle[3](index=3&type=chunk)[5](index=5&type=chunk) - Key secondary endpoints: Proportion of subjects achieving F-VASI75 at Week 24, percent change from baseline in F-VASI score at week 24[3](index=3&type=chunk)[5](index=5&type=chunk)[6](index=6&type=chunk) - Exploratory endpoint: Percent change from baseline in T-VASI score at week 24[3](index=3&type=chunk)[7](index=7&type=chunk) [Detailed Efficacy Results](index=2&type=section&id=Detailed%20Efficacy%20Results) This section details the specific numerical outcomes for the trial's efficacy endpoints, showing that while primary and key secondary endpoints were not met, the 3% Repibresib dose significantly improved percent change from baseline for F-VASI and T-VASI Primary Endpoint: Proportion of Subjects Achieving F-VASI50 at Week 24 | Endpoint at Week 24 | Repibresib 3% | Repibresib 2% | Repibresib 1% | Vehicle | | :------------------ | :------------ | :------------ | :------------ | :------ | | Proportion of Subjects Achieving F-VASI50 | 19.5% | 16.3% | 17.4% | 23.4% | | P-Value | 0.1245 | 0.6497 | 0.9718 | | Key Secondary Endpoint: Proportion of Subjects Achieving F-VASI75 at Week 24 | Endpoint at Week 24 | Repibresib 3% | Repibresib 2% | Repibresib 1% | Vehicle | | :------------------ | :------------ | :------------ | :------------ | :------ | | Proportion of Subjects Achieving F-VASI75 | 9.8% | 7.0% | 10.9% | 6.4% | | P-Value | 0.1468 | 0.4096 | 0.2946 | | Key Secondary Endpoint: Percent Change from Baseline in F-VASI at Week 24 | Endpoint at Week 24 | Repibresib 3% | Repibresib 2% | Repibresib 1% | Vehicle | | :------------------ | :------------ | :------------ | :------------ | :------ | | Mean Percent Change from Baseline in F-VASI, % (SD) | -43.6 (5.7) | -25.7 (5.7) | -30.2 (5.2) | -25.6 (4.9) | | P-Value | 0.0020 | 0.9892 | 0.4002 | | Exploratory Endpoint: Percent Change from Baseline in T-VASI at Week 24 | Endpoint at Week 24 | Repibresib 3% | Repibresib 2% | Repibresib 1% | Vehicle | | :------------------ | :------------ | :------------ | :------------ | :------ | | Mean Percent Change from Baseline in T-VASI, % (SD) | -28.3 (6.1) | -15.2 (6.1) | -16.4 (5.2) | -16.2 (4.9) | | P-Value | 0.0436 | 0.8757 | 0.9670 | | [Safety and Tolerability Profile](index=2&type=section&id=Safety%20and%20Tolerability%20Profile) Repibresib gel exhibited a higher rate of mostly mild, cutaneous treatment-emergent adverse events compared to vehicle, with application site pain being the most common, and no increased risk of thrombocytopenia or GI-related serious adverse events - Higher rate of treatment emergent adverse events (TEAE) for Repibresib gel compared to vehicle[8](index=8&type=chunk) - Most common TEAEs (>5%) were cutaneous, with application site pain being the most frequent (**Repibresib 3%: 14.0%; Vehicle: 3.8%**)[8](index=8&type=chunk) - **8 subjects** receiving Repibresib gel discontinued due to an AE, compared to none in the vehicle group[8](index=8&type=chunk) - Majority of skin-related TEAEs were mild (**76.0%**) and resolved during the study, with no clear dose-dependent increase in frequency[8](index=8&type=chunk) - One non-drug-related serious adverse event (cholelithiasis without obstruction) occurred in the Repibresib 1% cohort[8](index=8&type=chunk) - No increased risk of thrombocytopenia or GI-related serious adverse events was observed[8](index=8&type=chunk) [Financial Update](index=1&type=section&id=Financial%20Update) As of June 30, 2025, VYNE Therapeutics expects to report unaudited cash, cash equivalents, and investments of approximately $39.6 million, subject to finalization of financial results Unaudited Cash Position (as of June 30, 2025) | Metric | Amount | | :-------------------------------- | :------------- | | Cash, cash equivalents and investments | ~$39.6 million | - The cash estimate is preliminary and subject to change pending the actual results of, and completion of, the Company's condensed consolidated financial statements for the quarter ended June 30, 2025[14](index=14&type=chunk) [Product Candidate Information](index=2&type=section&id=Product%20Candidate%20Information) This section provides an overview of Repibresib, a pan-bromodomain BET inhibitor, and VYN202, an oral small molecule BET inhibitor, highlighting their design and therapeutic potential [About Repibresib](index=2&type=section&id=About%20Repibresib) Repibresib is a pan-bromodomain BET inhibitor designed for local administration as a "soft" drug, aiming for low systemic exposure to treat inflammatory conditions and showing preclinical efficacy - Repibresib is a pan-bromodomain BET inhibitor[9](index=9&type=chunk) - Designed for local administration as a "soft" drug to address inflammatory cell signaling pathways[9](index=9&type=chunk) - Provides low systemic exposure[9](index=9&type=chunk) - Produced consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity in preclinical models[9](index=9&type=chunk) [About VYN202](index=2&type=section&id=About%20VYN202) VYN202 is an innovative, oral small molecule BET inhibitor with potential class-leading selectivity for BD2 versus BD1, aiming to be a differentiated, non-biologic treatment for immuno-inflammatory conditions - VYN202 is an innovative, oral small molecule BET inhibitor[10](index=10&type=chunk) - Potential for class-leading selectivity and potency for BD2 vs. BD1[10](index=10&type=chunk) - Aims to be a differentiated, conveniently administered, non-biologic treatment for immuno-inflammatory indications[10](index=10&type=chunk) [Corporate Information and Disclosures](index=4&type=section&id=Corporate%20Information%20and%20Disclosures) This section provides details about VYNE Therapeutics Inc., investor relations contacts, and a cautionary statement regarding forward-looking statements and associated risks [About VYNE Therapeutics Inc.](index=4&type=section&id=About%20VYNE%20Therapeutics%20Inc.) VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for chronic inflammatory and immune-mediated conditions using its InhiBET™ platform - Clinical-stage biopharmaceutical company[12](index=12&type=chunk) - Focuses on developing differentiated therapies for chronic inflammatory and immune-mediated conditions with high unmet need[12](index=12&type=chunk) - Utilizes the InhiBET™ platform, comprising unique and proprietary BET inhibitors[12](index=12&type=chunk) - InhiBET™ inhibitors are designed to overcome limitations of early generation BET inhibitors via alternative administration routes and enhanced selectivity[12](index=12&type=chunk) [Investor Relations Contact](index=4&type=section&id=Investor%20Relations%20Contact) Investor relations inquiries can be directed to specified contacts at LifeSci Advisors, LLC or VYNE Therapeutics Inc., with VYNE also using its website for Regulation FD disclosures Investor Relations Contacts | Name | Affiliation | Phone | Email | | :----------- | :------------------ | :---------- | :---------------------- | | John Fraunces | LifeSci Advisors, LLC | 917-355-2395 | jfraunces@lifesciadvisors.com | | Tyler Zeronda | VYNE Therapeutics Inc. | 908-458-9106 | Tyler.Zeronda@VYNEtx.com | - VYNE uses its website (www.vynetherapeutics.com) to comply with disclosure obligations under Regulation FD[13](index=13&type=chunk) [Cautionary Statement Regarding Forward-Looking Statements](index=4&type=section&id=Cautionary%20Statement%20Regarding%20Forward-Looking%20Statements) This section highlights that the release contains forward-looking statements subject to risks, uncertainties, and assumptions that could cause actual results to differ materially, advising investors to review SEC filings for risk factors - The release contains forward-looking statements regarding clinical development, future expectations, plans, and prospects[14](index=14&type=chunk) - These statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially[14](index=14&type=chunk) - Risks include VYNE's ability to successfully develop its product candidates; the timing of commencement of future preclinical studies and clinical trials; VYNE's ability to complete and receive favorable results from clinical trials of its product candidates; VYNE's ability to find a partner for repibresib; VYNE's ability to obtain additional funding, either through equity or debt financing transactions or collaboration arrangements; and VYNE's ability to comply with various regulations applicable to its business[14](index=14&type=chunk) - The preliminary cash estimate for June 30, 2025, is unaudited and subject to change[14](index=14&type=chunk) - Investors should not rely on forward-looking statements as predictions and should review SEC filings for risk factors[14](index=14&type=chunk)

Core Insights - VYNE Therapeutics Inc. reported financial results for the quarter ended June 30, 2025, highlighting its focus on developing therapies for chronic inflammatory and immune-mediated conditions with high unmet needs [1][12] Pipeline Overview - VYNE's oral BD2-selective BET inhibitor, VYN202, has shown promising efficacy in a Phase 1b clinical trial for moderate to severe plaque psoriasis and potential in various other diseases [2][6] - The FDA had previously placed a clinical hold on the Phase 1b trial due to testicular toxicity observed in dogs, but lifted the hold for female subjects in June 2025 [6] - The company is seeking a partner for its topical BET inhibitor, repibresib, which has patent exclusivity until at least 2042 in the U.S. and 2040 in Europe and other major markets [2][6] Financial Results - As of June 30, 2025, VYNE reported revenues of $0.1 million, a decrease from $0.2 million in the same quarter of 2024, primarily from royalty revenue [8] - Research and development expenses decreased by 33.2% to $4.9 million compared to $7.3 million in the same quarter of 2024, driven by reduced expenses for repibresib and VYN202 [9] - General and administrative expenses also decreased by 17.0% to $2.7 million from $3.3 million in the prior year [10] - The net loss for the quarter was $5.8 million, or $0.13 per share, compared to a net loss of $9.4 million, or $0.22 per share, in the same quarter of 2024 [11] Cash Position - VYNE had $39.6 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which is expected to fund operations into the first half of 2027 [7]

Market Performance - U.S. stocks showed mixed trading results, with the Nasdaq Composite gaining approximately 0.5% [1] - The Dow increased by 0.02% to 44,639.69, while the S&P 500 rose by 0.21% to 6,384.38 [1] - Utilities shares experienced a rise of 0.8%, while energy stocks fell by 1.2% [1] Commodities - Crude oil prices increased by 0.8% to $69.73, while gold rose by 1% to $3,356.50 [5] - Silver prices decreased by 1.3% to $37.775, and copper fell by 0.9% to $5.5750 [5] European Markets - European shares were mostly higher, with the eurozone's STOXX 600 gaining 0.01% and Spain's IBEX 35 Index rising by 0.21% [6] - London's FTSE 100 fell by 0.08%, while Germany's DAX 40 and France's CAC 40 rose by 0.20% and 0.26%, respectively [6] Asian Markets - Asian markets closed mixed, with Japan's Nikkei 225 down by 0.05% and Hong Kong's Hang Seng down by 1.36% [7] - China's Shanghai Composite rose by 0.17%, and India's BSE Sensex gained 0.18% [7] Company Earnings - Wingstop Inc. shares surged by 24% to $360.20 after reporting better-than-expected second-quarter EPS and sales [9] - FTAI Aviation Ltd. shares increased by 20% to $137.34 following strong quarterly EPS and sales [9] - Rocky Brands Inc. shares rose by 26% to $29.00 after announcing better-than-expected quarterly earnings [9] - Vyne Therapeutics Inc. shares plummeted by 74% to $0.3764 after failing to meet trial endpoints [9] - Sos Ltd. shares dropped by 55% to $2.7184 after announcing a $7.5 million registered direct offering [9] - Avis Budget Group, Inc. shares fell by 15% to $172.40 following worse-than-expected quarterly EPS and sales [9] Economic Indicators - The U.S. economy expanded at an annualized rate of 3% in the second quarter, recovering from a 0.5% contraction in the previous quarter [11] - Private businesses added 104,000 jobs in July, surpassing market estimates of a 75,000 increase [11] - Crude oil inventories in the U.S. rose by 7.698 million barrels, contrasting with market expectations of a 2 million barrel decline [11]

Core Insights - VYNE Therapeutics announced that its Phase 2b trial for Repibresib gel in nonsegmental vitiligo did not meet its primary endpoint of achieving at least a 50% improvement in the Facial Vitiligo Area Scoring Index (F-VASI50) at week 24 compared to the vehicle group [1][2][4] - Despite missing the primary and key secondary endpoints, nominally statistically significant effects were observed in some exploratory endpoints, indicating potential efficacy at the highest dose [2][4] - The company plans to terminate the ongoing extension phase of the trial and seek an external partner for the continued development of Repibresib [1][4] Trial Details - The Phase 2b trial involved 177 subjects and was a randomized, double-blind, vehicle-controlled study assessing the safety and efficacy of Repibresib at concentrations of 1%, 2%, and 3% [3] - The trial was conducted across 45 sites in North America and evaluated multiple efficacy endpoints, including the primary endpoint of F-VASI50 and key secondary endpoints [3] Efficacy Results - The trial did not meet the primary endpoint, with only 19.5% of subjects in the 3% Repibresib group achieving F-VASI50 compared to 23.4% in the vehicle group [5] - For the key secondary endpoint of F-VASI75, 9.8% of subjects in the 3% group achieved this compared to 6.4% in the vehicle group [6] - The percent change from baseline in F-VASI score at week 24 showed a mean reduction of -43.6% for the 3% Repibresib group versus -25.6% for the vehicle group, indicating a statistically significant treatment effect [7] - The percent change from baseline in T-VASI score at week 24 also showed a significant reduction of -28.3% for the 3% Repibresib group compared to -16.2% for the vehicle group [8] Safety and Tolerability - The trial reported a higher rate of treatment-emergent adverse events (TEAEs) in subjects receiving Repibresib compared to the vehicle group, with application site pain being the most common adverse event [9] - Eight subjects discontinued due to adverse events in the Repibresib group, while none in the vehicle group experienced this [9] Financial Position - As of June 30, 2025, VYNE expects to report approximately $39.6 million in cash, cash equivalents, and investments [4]

Core Viewpoint - VYNE Therapeutics Inc. is advancing its VYN202 program for treating moderate-to-severe plaque psoriasis after the FDA lifted a clinical hold for female patients on lower doses, while further data is needed for male subjects [1][2][4] VYN202 Program Update - The FDA placed a clinical hold on the Phase 1b trial due to testicular toxicity observed in dogs, but has now lifted the hold for female patients on 0.25 mg and 0.5 mg doses [2] - The 1 mg dose was excluded from the revised protocol due to a lower safety margin [2] - A 12-week non-clinical toxicology study is required to resume trials in male subjects, with the study design agreed upon with the FDA [2] Clinical Data Insights - The clinical data from the Phase 1b trial included 7 enrolled subjects, with 6 treated with VYN202 and 1 with placebo [3][5] - No serious adverse events or treatment discontinuations were reported, and all subjects treated with VYN202 showed improvement in psoriasis symptoms [7] - PASI scores improved by approximately 27% after 1 week and up to 90% by week 8 [7] - Significant reductions in serum cytokine levels were observed in subjects treated with VYN202, while no changes were noted in the placebo group [7] Future Plans and Financial Outlook - The company will not enroll new patients in the Phase 1b psoriasis study, extending its expected cash runway into Q4 2026 [4] - Further updates on the VYN202 program will follow the release of top-line results from the ongoing Phase 2b study of repibresib gel for non-segmental vitiligo [4] About VYN202 - VYN202 is an oral small molecule BET inhibitor with potential class-leading selectivity and potency for BD2, aimed at providing a non-biologic treatment option for immuno-inflammatory conditions [10] About VYNE Therapeutics Inc. - VYNE is focused on developing differentiated therapies for chronic inflammatory and immune-mediated conditions, leveraging its proprietary BET inhibitors to overcome limitations of earlier generations [11]